Literature DB >> 12643887

Clinical and angiographic outcome of patients with mild coronary lesions treated with balloon angioplasty or coronary stenting. Implications for mechanical plaque sealing.

N Mercado1, W Maier, E Boersma, C Bucher, V de Valk, W W O'Neill, B J Gersh, B Meier, P W Serruys, W Wijns.   

Abstract

AIMS: To investigate the clinical and angiographic outcome of patients with mild coronary lesions treated with balloon angioplasty or coronary stenting (coronary plaque sealing, i.e. dilatation of angiographically non-significant lesions) compared to moderate and severe stenoses. METHODS AND
RESULTS: Patients with chronic stable angina and a single de novo lesion in a native coronary vessel scheduled to undergo percutaneous coronary intervention (PCI) were selected from 14 different studies. Off-line analysis of angiographic outcomes was assessed in all patients using identical and standardised methods of data acquisition, analysis and definitions. Clinical endpoints were adjudicated by independent clinical events committees. All quantitative coronary angiographic (QCA) analyses were performed in the same core laboratory. Stenosis severity prior to PCI was categorised into three groups: <50% diameter stenosis (DS), 50-99%DS and >99%DS pre. A total of 3812 patients were included in this study; 1484 patients (39%) were successfully treated with balloon angioplasty (BA) only and stented angioplasty was performed in 2328 patients (61%).One-year mortality and rate of non-fatal myocardial infarction (MI) (Kaplan-Meier) did not differ between BA and stented angioplasty for any of the stenosis severity categories. Following BA, the combined event rate (death and non-fatal MI) was 4.8, 4.6 and 0% in the <50, 50-99 and >99%DS categories, respectively. Following stented angioplasty, the combined event rate was 3.1, 4.4 and 4.8% in the same categories. The need for repeat revascularisation corrected for stenosis severity in the Cox proportional-hazards regression model was reduced by 20% after stented angioplasty (hazard ratio (HR) 0.80, 95%CI 0.69-0.93).
CONCLUSION: The concept of plaque sealing is appealing from the theoretical point of view. However, with current technology, plaque sealing cannot prevent death and future non-fatal MIs in the long-term because 1-year event rates after PCI of non-significant stenoses remain unacceptably elevated when compared with the estimated 1-year probability of a non-fatal MI in lesions with a <50%DS. Moreover, major adverse cardiac events at 1-year after PCI are not directly related to the degree of pre-procedural stenosis severity.

Entities:  

Mesh:

Year:  2003        PMID: 12643887     DOI: 10.1016/s0195-668x(02)00422-0

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  7 in total

Review 1.  Optimum guidance of complex PCI by coronary pressure measurement.

Authors:  Nico H J Pijls
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

Review 2.  Plaque sealing by coronary angioplasty.

Authors:  B Meier
Journal:  Heart       Date:  2004-12       Impact factor: 5.994

3.  Unstable or High Risk Plaque: How Do We Approach It?

Authors:  A B Mehta; Sameer Shah
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 4.  Drug-eluting stents and vulnerable plaque.

Authors:  Mehmet Cilingiroglu; Faisal Khan
Journal:  Curr Atheroscler Rep       Date:  2009-03       Impact factor: 5.113

5.  Virtual histology.

Authors:  Andreas König; Volker Klauss
Journal:  Heart       Date:  2007-05-13       Impact factor: 5.994

6.  Multi-Detector Coronary CT Imaging for the Identification of Coronary Artery Stenoses in a "Real-World" Population.

Authors:  Amgad N Makaryus; Sonia Henry; Lee Loewinger; John N Makaryus; Lawrence Boxt
Journal:  Clin Med Insights Cardiol       Date:  2015-01-05

7.  Prognostic irrelevance of plaque vulnerability following plaque sealing in high-risk patients with type 2 diabetes: an optical coherence tomography study.

Authors:  Rosalia Dettori; Andrea Milzi; Kathrin Burgmaier; Mohammad Almalla; Martin Hellmich; Nikolaus Marx; Sebastian Reith; Mathias Burgmaier
Journal:  Cardiovasc Diabetol       Date:  2020-11-12       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.